drugset / Trial / NCT06928753
Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
Phase 4
Recruiting
1800 enrolled
Centre Hospitalier Universitaire de la Réunion
ANRS, Emerging Infectious Diseases · collabARS La Réunion · collabDirection Générale de l'Offre de Soins · collabRégion La Réunion · collab
Non-randomizedParallel-groupOpen-labelOther
Summary
Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.
Timeline
- Start
- 2025-04-18
- Primary completion
- 2026-04
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CHIKUNGUNYA VIRUS, LIVE ATTENUATED | Vaccine | — | — |